The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease

Ignacio Munoz-Sanjuan, Gillian P. Bates

Research output: Contribution to journalLiterature reviewpeer-review

93 Citations (Scopus)

Abstract

Huntington disease (HD) is a dominantly inherited neurodegenerative disorder that results from expansion of the polyglutamine repeat in the huntingtin (HTT) gene. There are currently no effective treatments for this devastating disease. Given its monogenic nature, disease modification therapies for HD should be theoretically feasible. Currently, pharmacological therapies aimed at disease modification by altering levels of HTT protein are in late-stage preclinical development. Here, we review current efforts to develop new treatments for HD based on our current understanding of HTT function and the main pathological mechanisms. We emphasize the need to enhance translational efforts and highlight the importance of aligning the clinical and basic research communities to validate existing hypotheses in clinical studies. Human and animal therapeutic trials are presented with an emphasis on cellular and molecular mechanisms relevant to disease progression.
Original languageEnglish
Pages (from-to)476 - 483
Number of pages8
JournalJournal of Clinical Investigation
Volume121
Issue number2
DOIs
Publication statusPublished - 1 Feb 2011

Fingerprint

Dive into the research topics of 'The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease'. Together they form a unique fingerprint.

Cite this